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  EVIDENCE-BASED ANSWER 
Nebulized epinephrine decreases oxygen requirements, respiratory rate, wheezing, and retractions and may 
lower hospitalization rates and length of stay (Grade of Recommendation: A, based on consistent randomized 
controlled trials [RCTs] and systematic reviews). At best, other beta-2 agonists provide modest short-term 
improvement in mild to moderate bronchiolitis (Grade of Recommendation: A, consistent RCTs and systematic 
reviews), and may be indicated in patients with preexisting asthma. Discontinue bronchodilators if patients do 
not respond quickly, because the bronchodilators may cause respiratory deterioration (Grade of 
Recommendation: D, expert opinion). Supplemental oxygen for low oxygen saturation and suctioning may 
improve respiratory status (Grade of Recommendation: D, expert opinion). Chest physiotherapy (Grade of 
Recommendation: D, expert opinion), cool mist (Grade of Recommendation: D, expert opinion), and 
aerosolized saline (Grade of Recommendation: A, based on RCTs) are not recommended. Steroids, routine 
antibiotics, ribavirin, and pooled immunoglobulins play no role in previously healthy children (Grade of 
Recommendation: A, systematic review, RCT and meta-analysis). See the Table for a summary of therapeutic 
interventions for bronchiolitis. 
 
TABLE 
Therapeutic interventions for bronchiolitis 
Intervention Usefulness 
Grade of 
recommendation Notes 
Nebulized 
epinephrine 
Beneficial A Should be 
discontinued 
promptly in 
the absence 
of response 
Beta-2 agonists Not 
beneficial 
A May be useful 
in patients 
with 
preexisting 
asthma 
Corticosteroids Not 
beneficial 
A Not shown to 
impact clinical 
score or 
length of 
hospital stay 
Supplemental 
oxygen, 
suctioning 
Beneficial D Initiate at 
91% and 
wean at 94% 
  EVIDENCE SUMMARY 
Most trials of bronchiolitis treatment suffer from 2 constraints: possible inclusion of patients with asthma and 
inconsistent outcome measures. Five trials of nebulized epinephrine, involving 225 children, have been 
published in the last decade. All have shown clinical improvement in measures such as respiratory rate, 
wheezing, retractions, hospital admission rates, and length of stay.1 
Data from other clinical trials, meta-analyses, and a comprehensive Cochrane systematic review do not 
support the routine use of selective beta-2 agonists. Studies with unselected patients noted some benefit, 
which may reflect the inclusion of asthmatic children, or the effects of suctioning in combination with 
inhalational therapy. Large proportions of patients admitted to hospital with bronchiolitis receive 
bronchodilators, and many physicians continue to advocate their use.2 The cost of routine bronchodilators for 
children with bronchiolitis may be as high as $37.5 million per year.2 
One systematic review and 8 RCTs found conflicting evidence on the effects of corticosteroids.3 Steroid 
therapy, given as inhalations, intravenously, orally, or intramuscularly, does not have a consistent effect on 
clinical status or on length of stay.4 
A 1997 systematic review showed that ribavirin had no significant effect on mortality or the risk of respiratory 
deterioration in children admitted to hospital with respiratory syncytial virus (RSV) bronchiolitis.3 In fact, cohort 
studies and randomized trials have shown that ribavirin use is associated with an increase in the number of 
days of mechanical ventilation, intensive care unit stay, and hospitalizations.4 
Passive immunotherapy with pooled immunoglobulins remains controversial and is undergoing intense study.4 
Three RCTs failed to show any effect on length of hospital stay, and subsequent studies of an RSV-specific 
humanized monoclonal antibody (palivizumab) have not shown improvements in outcome. 
The evidence supporting the use of supplemental oxygen and suctioning of respiratory secretions is limited to 
expert opinion.5 
  RECOMMENDATIONS FROM OTHERS 
Most pediatric infectious diseases specialists surveyed in Europe recommend bronchodilators. However, 
bronchodilators are seldom used to treat bronchiolitis in the United Kingdom.2 The present consensus from the 
American Academy of Pediatrics6 states that ribavirin should be considered in infants with underlying 
congenital heart disease, lung disease, or immunosuppression, or for infants requiring mechanical ventilation. 
CLINICAL COMMENTARY 
Harold  A.  Williamson  Jr,  MD, MSPH 
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Wheezing children are usually hospitalized when they have hypoxemia, lethargy, and 
fatigue associated with tachypnea and decreased oral intake. Because of the difficulty in 
differentiating between “bronchiolitis” and a first episode of “asthma,” many wheezing 
children will continue to receive bronchodilators. Discontinuing bronchodilators seems 
prudent if oxygenation and respiratory rate do not improve after 6 hours. Supportive care 
with fluids, oxygen, and suctioning of secretions is usually all that is required in even 
moderately sick patients. As in other situations involving sick children, the temptation to 
intervene is overwhelming, hence the many ineffective treatments available. RSV is by far 
the most common viral pathogen causing bronchiolitis; effective immunization for RSV 
would probably markedly decrease hospitalizations from bronchiolitis. 
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